

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Abecassis Michael M (Last) (First) (Middle) 23046 AVENIDA DE LA CARLOTA, SUITE 600 (Street) LAGUNA HILLS, CA 92653 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/10/2021	3. Issuer Name and Ticker or Trading Symbol PharmaCyte Biotech, Inc. [PMCB]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
		5. If Amendment, Date Original Filed(Month/Day/Year)	
6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,667 (1)	D	
Common Stock	800 (1)	I	By Transplant Consulting LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	07/03/2017	07/03/2022	Common Stock	334 (1)	\$ 87 (2)	D	
Stock Option (right to buy)	07/03/2017	07/03/2022	Common Stock	800 (1)	\$ 87 (2)	I	By Transplant Consulting LLC
Stock Option (right to buy)	07/01/2018	07/01/2023	Common Stock	334 (1)	\$ 102.45 (2)	D	
Stock Option (right to buy)	07/01/2019	07/01/2024	Common Stock	334 (1)	\$ 55.5 (2)	D	
Stock Option (right to buy)	07/01/2020	07/01/2025	Common Stock	334 (1)	\$ 37.05 (2)	D	
Stock Option (right to buy)	07/01/2021	06/30/2026	Common Stock	334 (1)	\$ 16.2 (2)	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Abecassis Michael M 23046 AVENIDA DE LA CARLOTA SUITE 600 LAGUNA HILLS, CA 92653	X			

Signatures

/s/ Michael M. Abecassis	08/20/2021
--------------------------	------------

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
- (2) The exercise price has been adjusted to reflect the Reverse Split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.